What question did this study set out to answer?

To discuss the effectiveness of rituximab and IVIG as treatments for refractory eosinophilic fasciitis.

January 6, 2026Clinical Case Reports0 citationsOpen Access

Rituximab and Intravenous Immunoglobulin ( IVIG ) for Refractory Eosinophilic Fasciitis: A Case Report

MSM SahebariMashhad University of Medical Sciences MKMotahhareh KarimoddiniMashhad University of Medical Sciences NMNaser Tayyebi Meibodi

Key Points

To discuss the effectiveness of rituximab and IVIG as treatments for refractory eosinophilic fasciitis.
Case report of a 40-year-old man with eosinophilic fasciitis
Documented treatment with rituximab and intravenous immunoglobulin (IVIG)
Outcome assessment of treatment response
The patient did not respond to standard treatments initially
Improvement was observed after administration of rituximab and IVIG
Further studies are needed to assess long-term safety and effectiveness

Abstract

ABSTRACT Eosinophilic fasciitis (EF) is a rare condition with an unknown cause. This case study showed that a 40‐year‐old man with EF did not respond to standard treatments but improved after receiving rituximab and intravenous immunoglobulin (IVIG). Further studies are needed to confirm rituximab's effectiveness and long‐term safety for EF.

问 AI

Bookmark

View Full Paper